Eleva Appoints Martin Bauer, MD as Chief Medical Officer Adding Substantial Clinical Development Expertise to the Organization

Eleva’s Factor H (CPV-104) program to enter clinic in 2025 in C3G, with dry AMD identified as potential second indication

Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough moss-based platform, announced today the appointment of Dr. Martin Bauer, MD, as new Chief Medical Officer. His appointment reflects the growing maturity of Eleva’s proprietary pipeline, which includes Eleva’s Factor H (CPV-104) program, a novel complement regulator with therapeutic potential in several indications, and aGal (RPV-001), a best-in-class approach to treat Fabry disease.

Martin Bauer joins Eleva with over two decades of clinical development expertise, having held various management positions of increasing responsibility. His roles include senior and leadership positions at Atriva Therapeutics, Merck, Basilea, Otsuka, ICON, and Boehringer Ingelheim. He is board-certified in Anesthesiology, Rescue Medicine, and Medical Informatics, and has over 10 years of experience working in academic hospitals. Martin Bauer earned his MD from Julius-Maximilians University of Würzburg, Germany.

“With the clinical trial start for our second fully owned drug development program on the horizon, we have decided to appoint an experienced Chief Medical Officer orchestrating all of these activities,” commented Björn Cochlovius Ph.D., Chief Executive Officer of Eleva. “Martin’s deep expertise in clinical development across several indications and modalities will be very valuable for Eleva’s continued growth as a drug development organization.”

Commenting on his appointment, Martin Bauer added: “I’m thrilled to support Eleva as the company further strengthens its drug development activities with additional pipeline programs and potentially new indications being explored. Our Factor H program in particular has the potential to unlock a novel therapeutic mode-of-action that is clearly differentiated from the standard-of-care.”

ABOUT ELEVA

Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough technology platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential.